AMACR (RM), 2X

$394.00

SKU: OAA 3125 G10 Categories: , ,

α-Methylacyl coenzyme A racemase (AMACR), also known as P504S, is a peroxisomal and mitochondrial enzyme that plays a role in bile acid synthesis and β oxidation of branched chain fatty acids (1).

AMACR was initially identified from a cDNA library as a gene that is overexpressed in human prostate cancer; with little or no expression in normal or benign prostate glands (2-3). In immunohistochemistry, AMACR has been shown to be a marker of prostatic adenocarcinoma (2-5).

Additionally, prostate glands involved in prostatic intraepithelial neoplasia (PIN), have been found
to express AMACR; whereas AMACR was nearly undetectable in benign glands (5-6).

Intended Use

ASR

Volume

10 ml

Format

ONCORE

Source

Rabbit Monoclonal

Clone

13H4

Isotype

IgG

Download Data Sheet
Download SDS Sheet


1. Ferdinandusse S, et al. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res. 2000 Nov; 41 (11):1890-6.
2. Xu J, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 2000 Mar 15; 60(6):1677-82.
3. Rubin MA, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002 Apr 3; 287 (13):1662-70.
4. Luo J, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002 Apr 15; 62(8):2220-6.
5. Zhou M, et al. Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol. 2002 Jul; 26(7):926-31.
6. Wu CL, et al. Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol. 2004 Aug; 35(8):1008-13.
7. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
8. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.